Literature DB >> 1271535

Replication of mycoplasmavirus MVL51. IV. Inhibition of viral synthesis by rifampin.

J Das, J Maniloff.   

Abstract

The effect of rifampin on the replication of MVL51, a bullet-shaped mycoplasmavirus with single-stranded circular DNA of molecular weight 2 X 10(6), has been examined in a rifampin-resistant host cell. Rifampin does not block the early steps in MVL51 infection but does decrease the total amount of parental viral DNA taken up. The single-stranded parental viral DNA that enters the cell is found in membrane-associated, double-stranded DNA replicative forms I and II. Rifampin had no significant effect on the synthesis of progeny viral DNA RFI and RFII early in infection and SSI (single-stranded progeny viral chromosomes) later in infection. The rifampin block in virus synthesis was found to be in the step converting SSI into assembled virions. Rifampin was shown to affect the synthesis of virus-specific RNA, Which suggests that viral transcription is necessary for virion assembly.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1271535      PMCID: PMC354797          DOI: 10.1128/JVI.18.3.969-976.1976

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  11 in total

1.  Replication of mycoplasmavirus MVL51: I. Replicative intermediates.

Authors:  J Das; J Maniloff
Journal:  Biochem Biophys Res Commun       Date:  1975-09-16       Impact factor: 3.575

2.  Complex of bacteriophage M13 single-stranded DNA and gene 5 protein.

Authors:  D Pratt; P Laws; J Griffith
Journal:  J Mol Biol       Date:  1974-02-05       Impact factor: 5.469

3.  Inhibition of M13 phage synthesis by rifampicin in some rifampicin-resistant Escherichia coli mutants.

Authors:  S Mitra
Journal:  Virology       Date:  1972-11       Impact factor: 3.616

4.  Eagle's basal medium as a defined medium for Mycoplasma studies.

Authors:  D C Quinlan; A Liss; J Maniloff
Journal:  Microbios       Date:  1972 Sep-Oct

5.  Characterization of mycoplasmatales virus DNA.

Authors:  A Liss; J Maniloff
Journal:  Biochem Biophys Res Commun       Date:  1973-03-05       Impact factor: 3.575

6.  Infection of Acholeplasma laidlawii by MVL51 virus.

Authors:  A Liss; J Maniloff
Journal:  Virology       Date:  1973-09       Impact factor: 3.616

7.  Characterization of T7-specific ribonucleic acid polymerase. II. Inhibitors of the enzyme and their application to the study of the enzymatic reaction.

Authors:  M Chamberlin; J Ring
Journal:  J Biol Chem       Date:  1973-03-25       Impact factor: 5.157

Review 8.  Regulation of RNA synthesis.

Authors:  E K Bautz
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1972

9.  A possible role for RNA polymerase in the initiation of M13 DNA synthesis.

Authors:  D Brutlag; R Schekman; A Kornberg
Journal:  Proc Natl Acad Sci U S A       Date:  1971-11       Impact factor: 11.205

10.  New small polypeptides associated with DNA-dependent RNA polymerase of Escherichia coli after infection with bacteriophage T4.

Authors:  A Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

View more
  5 in total

1.  Antibiotic sensitivity and mutation rates to antibiotic resistance in Mycoplasma mycoides ssp. mycoides.

Authors:  D H Lee; R J Miles; J R Inal
Journal:  Epidemiol Infect       Date:  1987-06       Impact factor: 2.451

Review 2.  The mycoplasmas.

Authors:  S Razin
Journal:  Microbiol Rev       Date:  1978-06

Review 3.  Molecular biology and genetics of mycoplasmas (Mollicutes).

Authors:  S Razin
Journal:  Microbiol Rev       Date:  1985-12

4.  Probable insensitivity of mollicutes to rifampin and characterization of spiroplasmal DNA-dependent RNA polymerase.

Authors:  A P Gadeau; C Mouches; J M Bove
Journal:  J Bacteriol       Date:  1986-06       Impact factor: 3.490

5.  Replication of mycoplasma virus L51. VII. Effect of chloramphenicol on the synthesis of DNA replicative intermediates.

Authors:  J Das; J Maniloff
Journal:  J Virol       Date:  1982-12       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.